Quantitative immunohistochemistry in lung cancer: Clinical perspective

Folia Histochemica et Cytobiologica

Volumn 48, Issue 1, 2010, Pages 7-11

  Szutowicz, Ewa ^a   Dziadziuszko, Rafał ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

Author keywords

Clinical trials; Immunohistochemistry; Lung cancer; Protein expression

Indexed keywords

ALKYLATING AGENT; CISPLATIN; CYCLIN D1; CYCLIN D3; CYCLIN DEPENDENT KINASE INHIBITOR 1B; CYCLIN E; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; GEFITINIB; GEMCITABINE; KI 67 ANTIGEN; MULTIDRUG RESISTANCE PROTEIN 1; MULTIDRUG RESISTANCE PROTEIN 2; NAVELBINE; PLACEBO; PLATINUM COMPLEX; PROTEIN MSH2; PROTEIN P53; SOMATOMEDIN C RECEPTOR; TAXANE DERIVATIVE;

CANCER PATIENT; CANCER RESEARCH; CANCER THERAPY; CLINICAL TRIAL; HUMAN; IMMUNOHISTOCHEMISTRY; LUNG CANCER; LUNG NON SMALL CELL CANCER; OUTCOME ASSESSMENT; PREDICTION; PROGNOSIS; QUANTITATIVE HISTOCHEMISTRY; REVIEW;

EID: 77954377964     PISSN: 02398508     EISSN: None     Source Type: Journal    
DOI: 10.2478/v10042-010-0014-2     Document Type: Review

References (28)

1. Parkin DM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin. 2005;55:74-108.
2. Cappuzzo F, Hirsch FR, Rossi E et al. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in nonsmall- cell lung cancer. J Natl Cancer Inst. 2005;97:643-55.
3. Clark GM, Zborowski DM, Culbertson JL et al. Clinical utility of epidermal growth factor receptor expression for selecting patients with advanced non-small cell lung cancer for treatment with erlotinib. J Thorac Oncol. 2006;1:837-46.
4. Olaussen KA, Dunant A, Fouret P et al. DNA repair by ERCC1 in non-small-cell lung cancer and cisplatin-based adjuvant chemotherapy. N Engl J Med. 2006;355:983-91.
5. Shepherd FA, Rodrigues PJ, Ciuleanu T et al. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med. 2005;353:123-32.
6. Thatcher N, Chang A, Parikh P et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet. 2005;366:1527-37.
7. Hirsch FR, Varella-Garcia M, Bunn PA Jr et al. Molecular predictors of outcome with gefitinib in a phase III placebocontrolled study in advanced non-small-cell lung cancer. J Clin Oncol. 2006;24:5034-42.
8. Tsao MS, Sakurada A, Cutz JC et al. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med. 2005;353:133-44.
9. Hirsch FR, Dziadziuszko R, Thatcher N et al. Epidermal growth factor receptor immunohistochemistry: comparison of antibodies and cutoff points to predict benefit from gefitinib in a phase 3 placebo-controlled study in advanced nonsmallcell lung cancer. Cancer. 2008;112:1114-21.
10. Taillade L, Penault-Llorca F, Boulet T et al. Immunohistochemichal expression of biomarkers: a comparative study between diagnostic bronchial biopsies and surgical specimens of non-small-cell lung cancer. Ann Oncol. 2007;18:1043-50.
11. Ang KK, Berkey BA, Tu X et al. Impact of epidermal growth factor receptor expression on survival and pattern of relapse in patients with advanced head and neck carcinoma. Cancer Res. 2002;62:7350-6.
12. Zheng Z, Chen T, Li X et al. DNA synthesis and repair genes RRM1 and ERCC1 in lung cancer. N Engl J Med. 2007;356: 800-8.
13. Jassem J, Skokowski J, Dziadziuszko R et al. Results of surgical treatment of non-small cell lung cancer: validation of the new postoperative pathologic TNM classification. J Thorac Cardiovasc Surg. 2000;119:1141-6.
14. Kwiatkowski DJ, Harpole DH Jr, Godleski J et al. Molecular pathologic substaging in 244 stage I non-small-cell lung cancer patients: clinical implications. J Clin Oncol. 1998;16: 2468-77.
15. D'Amico TA, Aloia TA, Moore MB et al. Molecular biologic substaging of stage I lung cancer according to gender and histology. Ann Thorac Surg. 2000;69:882-6.
16. Chen HY, Yu SL, Chen CH et al. A five-gene signature and clinical outcome in non-small-cell lung cancer. N Engl J Med. 2007;356:11-20.
17. Potti A, Mukherjee S, Petersen R et al. A genomic strategy to refine prognosis in early-stage non-small-cell lung cancer. N Engl J Med. 2006;355:570-80.
18. Raponi M, Dossey L, Jatkoe T et al. MicroRNA classifiers for predicting prognosis of squamous cell lung cancer. Cancer Res. 2009;69:5776-83.
19. Shedden K, Taylor JM, Enkemann SA et al. Gene expressionbased survival prediction in lung adenocarcinoma: a multisite, blinded validation study. Nat Med. 2008;14:822-7.
20. Skrzypski M, Jassem E, Taron M et al. Three-gene expression signature predicts survival in early-stage squamous cell carcinoma of the lung. Clin Cancer Res. 2008;14:4794-9.
21. Ceppi P, Volante M, Novello S et al. ERCC1 and RRM1 gene expressions but not EGFR are predictive of shorter survival in advanced non-small-cell lung cancer treated with cisplatin and gemcitabine. Ann Oncol. 2006;17:1818-25.
22. Fouret P, Planchard D, Mendiboure J et al. MSH2 and adjuvant cisplatin-based chemotherapy in non-small cell lung cancer. J Clin Oncol. 2009;27:18(suppl; abstr CRA7502).
23. Bepler G, Kusmartseva I, Sharma S et al. RRM1 modulated in vitro and in vivo efficacy of gemcitabine and platinum in non-small-cell lung cancer. J Clin Oncol. 2006;24:4731-7.
24. Taron M, Rosell R, Felip E et al. BRCA1 mRNA expression levels as an indicator of chemoresistance in lung cancer. Hum Mol Genet. 2004;13:2443-9.
25. Kennedy RD, Quinn JE, Mullan PB, Johnston PG, Harkin DP. The role of BRCA1 in the cellular response to chemotherapy. J Natl Cancer Inst. 2004;96:1659-68.
26. Filipits M, Pirker R, Dunant A et al. Cell cycle regulators and outcome of adjuvant cisplatin-based chemotherapy in completely resected non-small-cell lung cancer: the International Adjuvant Lung Cancer Trial Biologic Program. J Clin Oncol. 2007;25:2735-40.
27. Tsao MS, Aviel-Ronen S, Ding K et al. MSH2 and cisplatinbased adjuvant chemotherapy in non-small cell lung cancer. J Clin Oncol. 2007;25:5240-7.
28. Filipits M, Haddad V, Schmid K et al. Multidrug resistance proteins do not predict benefit of adjuvant chemotherapy in patients with completely resected non-small cell lung cancer: International Adjuvant Lung Cancer Trial Biologic Program. Clin Cancer Res. 2007;13:3892-8.